106 related articles for article (PubMed ID: 1313273)
1. Low-Km cyclic AMP phosphodiesterase from human platelets. Stimulation of activity by phosphorylation of the enzyme and affinity labeling of the active site.
Grant PG; DeCamp DL; Bailey JM; Colman RF; Colman RW
Adv Second Messenger Phosphoprotein Res; 1992; 25():73-85. PubMed ID: 1313273
[No Abstract] [Full Text] [Related]
2. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
3. Activation of cyclic GMP-binding and cyclic AMP-specific phosphodiesterases of rat platelets by a mechanism involving cyclic AMP-dependent phosphorylation.
Tremblay J; Lachance B; Hamet P
J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(4):397-411. PubMed ID: 2411769
[TBL] [Abstract][Full Text] [Related]
4. Intact cell and cell-free phosphorylation and concomitant activation of a low Km, cAMP phosphodiesterase found in human platelets.
Macphee CH; Reifsnyder DH; Moore TA; Beavo JA
J Cyclic Nucleotide Protein Phosphor Res; 1986-1987; 11(7):487-96. PubMed ID: 2831258
[TBL] [Abstract][Full Text] [Related]
5. Calmodulin sensitive phosphodiesterase of porcine cerebral cortex: kinetic behavior, calmodulin activation, and stability.
Keravis TM; Duemler BH; Wells JN
J Cyclic Nucleotide Protein Phosphor Res; 1986; 11(5):365-72. PubMed ID: 3040819
[TBL] [Abstract][Full Text] [Related]
6. [Interaction between cyclic adenosine-3':5'-monophosphate phosphodiesterase and structural analogs of the substrate].
Kochetkova MN; Guliaev NN; Tunitskaia VL; Severin ES
Biokhimiia; 1981 Feb; 46(2):353-60. PubMed ID: 6264977
[TBL] [Abstract][Full Text] [Related]
7. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics.
Weishaar RE; Quade MM; Schenden JA; Evans DB
J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(6):551-64. PubMed ID: 3003170
[TBL] [Abstract][Full Text] [Related]
8. [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].
Medvedeva MV
Biokhimiia; 1995 Mar; 60(3):364-86. PubMed ID: 7734612
[TBL] [Abstract][Full Text] [Related]
9. Cyclic nucleotides and cyclic nucleotide phosphodiesterases in kidneys from rats with experimental diabetes.
Hoskins B; Luong HB
Res Commun Chem Pathol Pharmacol; 1981 Aug; 33(2):381-4. PubMed ID: 6272381
[TBL] [Abstract][Full Text] [Related]
10. A comparative kinetic study of bovine calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes utilizing cAMP, cGMP and their 2'-O-anthraniloyl-,2'-O-(N-methylanthraniloyl)-derivatives as substrates.
Grewal J; Karuppiah N; Mutus B
Biochem Int; 1989 Dec; 19(6):1287-95. PubMed ID: 2561449
[TBL] [Abstract][Full Text] [Related]
11. A reversed-phase HPLC-based method for the assay of cyclic nucleotide phosphodiesterase activity.
Abbott BM; Thompson PE
Anal Biochem; 2005 Apr; 339(1):185-7. PubMed ID: 15766728
[No Abstract] [Full Text] [Related]
12. [Phosphodiesterases of cyclic GMP].
Wróblewska H; Gorczyca WA
Postepy Hig Med Dosw; 2001; 55(5):611-27. PubMed ID: 11795198
[TBL] [Abstract][Full Text] [Related]
13. Insulin controls intracellular cyclic AMP concentrations in hepatocytes by activating specific cyclic AMP phosphodiesterases: phosphorylation of the peripheral plasma membrane enzyme.
Houslay MD; Wallace AV; Marchmont RJ; Martin BR; Heyworth CM
Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():159-76. PubMed ID: 6326521
[No Abstract] [Full Text] [Related]
14. Irreversible inhibition of calmodulin-sensitive cyclic nucleotide phosphodiesterase.
Sullivan TA; Duemler BH; Kuttesch NJ; Keravis TM; Wells JN
J Cyclic Nucleotide Protein Phosphor Res; 1986; 11(5):355-64. PubMed ID: 2442214
[TBL] [Abstract][Full Text] [Related]
15. [Activity of protein kinases and phosphodiesterases in the cell cycle of Ph. polycephalum].
Trakht NN; Grozdova ID; Severin ES; Gnuchev NV
Biokhimiia; 1980 Apr; 45(4):636-43. PubMed ID: 6246974
[No Abstract] [Full Text] [Related]
16. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase--basic and potential clinical applications.
Hidaka H; Endo T
Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():245-59. PubMed ID: 6144253
[No Abstract] [Full Text] [Related]
17. Cyclic GMP binding and phosphodiesterase: implication for platelet function.
Hamet P; Coquil JF; Bousseau-Lafortune S; Franks DJ; Tremblay J
Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():119-36. PubMed ID: 6202123
[No Abstract] [Full Text] [Related]
18. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
19. [Kinetic properties and regulation of cyclic nucleotide phosphodiesterases in lymphoid cells].
Azhaeva EV; Severin ES
Bioorg Khim; 1987 Sep; 13(9):1157-63. PubMed ID: 2827690
[TBL] [Abstract][Full Text] [Related]
20. Cyclic nucleotide phosphodiesterase activity in patients with obstructive airways disease.
Polson JB; Krzanowski JJ; Goldman AL; Szentivanyi A
Allergol Immunopathol (Madr); 1982; 10(2):101-4. PubMed ID: 6125092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
